Also the NK activating ligand MICB was induced/up-regulated by guadecitabine and DAC treatment in 57.1% (8/14) and by AZA in 14.2% (2/14), while MICA was up-regulated (FC ≥2) by guadecitabine and DAC treatment in 14.2% (2/14) and by AZA in 7.1% (1/14) of melanoma cell lines (Supplementary Tables 17, 18). Here, MICB is linked to melanoma.